Association between gastric cancer and -1993 polymorphism of TBX21 gene

Table 1 Distribution of TBX21 -1993T/C allelic frequencies in cases and controls n (%)

Variables	Case	Control	Adjusted OR (95% CI)	P trend
Age (yr) (mean ± SD)	41.14 ± 7.10	41.69 ± 8.83		0.8841
Gender
Male	124 (56.36)	143 (54.58)		0.6952
Female	96 (43.64)	119 (45.42)
Smoking status
Never	160 (72.73)	201 (76.72)		0.3142
Always	60 (27.27)	61 (23.28)
Drinking status
Never	149 (67.73)	188 (71.76)		0.3372
Always	71 (32.27)	74 (28.24)
Family history of cancer
No	181 (82.27)	240 (91.60)		0.0022
Yes	39 (17.73)	22 (8.40)
TBX21 -1993
T	356 (80.91)	473 (90.27)	1.00	-
C	84 (19.09)	51 (9.73)	2.06 (1.44-2.96)	< 0.0012
T/T	154 (70.00)	219 (83.59)	1.00	-
T/C	48 (21.82)	35 (13.36)	1.84 (1.13-3.01)	0.0153
C/C	18 (8.18)	8 (3.05)	3.42 (1.41-8.31)	0.0073

¹Mann-Whitney U test;

²χ² test;

³Multivariate unconditional logistic regression model. SD: Standard deviation; CI: Confidence interval; OR: Odds ratio.

Table 2 Multivariate logistic regression analysis of TBX21 -1993T/C stratified by the selected variables

Variables	Cases/controls		Adjusted OR (95% CI)	P
	T/T	T/C + C/C
Gender
Male	82/118	42/25	2.37 (1.31-4.31)	0.005
Female	72/101	24/18	1.89 (0.95-3.76)	0.071
Age (yr)
< 55	94/114	50/27	2.79 (1.61-4.81)	< 0.001
55–65	56/59	15/11	2.13 (1.36-3.31)	0.001
> 65	4/16	1/5	0.58 (0.04-7.92)	0.683
Smoking status
Never	118/167	42/34	1.77 (1.06-2.97)	0.029
Always	36/52	24/9	3.38 (1.31-8.71)	0.012
Drinking status
Never	105/155	44/33	2.00 (1.18-3.89)	0.010
Always	49/64	22/10	2.48 (1.04-5.90)	0.040
Family history of cancer
No	131/201	50/39	1.99 (1.23-3.21)	0.005
Yes	23/18	16/4	3.99 (1.06-15.03)	0.041

CI: Confidence interval; OR: Odds ratio.

Table 3 Clinicopathological characteristics analysis of 220 gastric cancer patients and TBX21 -1993T/C polymorphism n (%)

Variables	All	T/T	T/C	C/C	Adjusted OR (95% CI)	P
Age (yr)
≥ 60	26 (11.82)	21 (80.77)	3 (11.54)	2 (7.69)	1.93 (0.68-5.47)	0.218
< 60	194 (88.18)	133 (68.55)	45 (23.20)	16 (8.25)
Gender
Male	124 (56.36)	82 (66.13)	29 (23.39)	13 (10.48)	0.70 (0.32-1.56)	0.388
Female	96 (43.64)	72 (75.00)	19 (19.79)	5 (5.21)
Tumor size
≥ 5 cm	123 (55.91)	84 (68.29)	30 (24.39)	9 (7.32)	0.75 (0.40-1.41)	0.369
< 5 cm	97 (44.09)	70 (72.16)	18 (18.56)	9 (9.28)
Degree of differentiation
G1-2	107 (48.64)	70 (65.42)	23 (21.50)	14 (13.08)	1.64 (0.87-3.07)	0.124
G3-4	113 (51.36)	84 (74.34)	25 (22.12)	4 (3.54)
TNM stage
Stage I/II	67 (30.45)	47 (70.15)	13 (19.40)	7 (10.45)	0.73 (0.36-1.46)	0.370
Stage III/IV	153 (69.55)	107 (69.93)	35 (22.88)	11 (7.19)
Lymph node status
N0	78 (35.45)	66 (84.62)	6 (7.69)	6 (7.69)	4.02 (1.87-8.66)	< 0.001
N1-3	142 (64.55)	88 (61.97)	42 (29.58)	12 (8.45)
Distant metastasis
M0	148 (67.27)	121 (81.76)	18 (12.16)	9 (6.08)	7.02 (3.44-14.34)	< 0.001
M1	72 (32.73)	33 (45.83)	30 (41.67)	9 (12.50)

CI: Confidence interval; OR: Odds ratio.